K36 Therapeutics Stock

K36 Therapeutics translate epigenetic modulation of oncogenic pathways into small molecule therapies.

Sign up today and learn more about K36 Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About K36 Therapeutics Stock

K36 Therapeutics translate epigenetic modulation of oncogenic pathways into small molecule therapies.

Funding History

December 2021$30.0M
June 2023$70.0M

Management

Board of Directors

Chong Xu

Board of Directors

Melissa McCracken

Board of Directors

Lori Kunkel

Board of Directors

Jason Rhodes

President and Chief Executive Officer

Terrence Connolly

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo